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Background: Gelsemium sempervirens L. (Gelsemium s.) is a traditional medicinal plant, employed as an anxiolytic at
ultra-low doses and animal models recently confirmed this activity. However the mechanisms by which it might
operate on the nervous system are largely unknown. This work investigates the gene expression of a human neurocyte
cell line treated with increasing dilutions of Gelsemium s. extract.
Methods: Starting from the crude extract, six 100 × (centesimal, c) dilutions of Gelsemium s. (2c, 3c, 4c, 5c, 9c and 30c)
were prepared according to the French homeopathic pharmacopoeia. Human SH-SY5Y neuroblastoma cells were
exposed for 24 h to test dilutions, and their transcriptome compared by microarray to that of cells treated with control
vehicle solutions.
Results: Exposure to the Gelsemium s. 2c dilution (the highest dose employed, corresponding to a gelsemine
concentration of 6.5 × 10−9 M) significantly changed the expression of 56 genes, of which 49 were down-regulated and
7 were overexpressed. Several of the down-regulated genes belonged to G-protein coupled receptor signaling
pathways, calcium homeostasis, inflammatory response and neuropeptide receptors. Fisher exact test, applied to
the group of 49 genes down-regulated by Gelsemium s. 2c, showed that the direction of effects was significantly
maintained across the treatment with high homeopathic dilutions, even though the size of the differences was
distributed in a small range.
Conclusions: The study shows that Gelsemium s., a medicinal plant used in traditional remedies and
homeopathy, modulates a series of genes involved in neuronal function. A small, but statistically significant,
response was detected even to very low doses/high dilutions (up to 30c), indicating that the human neurocyte
genome is extremely sensitive to this regulation.Background
Gelsemium sempervirens (Gelsemium s.), also called yel-
low jasmine, is a plant belonging to the Loganiaceae
family. All parts of the plant contain the major active
principle gelsemine as well as other toxic strychnine-
related alkaloids, such as gelseminine and sempervirine
[1-3]. In the phytotherapy literature, Gelsemium s. has
been reported to show sedative, analgesic and anti-seizure
properties [4,5] while in the homeopathic Materia Medica
and literature, Gelsemium s. is described as a remedy
for a variety of anxiety-like psychological and behavioral* Correspondence: paolo.bellavite@univr.it
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reproduction in any medium, provided the orsymptoms [6-9]. The anxiolytic, antidepressant and/or
analgesic action of Gelsemium s. extracts and its purified
components has been recently demonstrated in animal
models [10-16]. Other reports in the literature suggest
this plant species may exhibit anticancer and immune-
modulating activity [17-20].
The question of dosage is obviously central to
pharmacology and of particular interest in homeopathic
pharmacopoeia, where the procedure of serial dilutions
followed by shaking has sparked much debate. The
original extract (Mother Tincture, MT) is generally
obtained by grinding the medicinal plant matter with
a mortar and pestle and dissolving it in ethanolic solution.
According to the most widely-used French pharmacopoeia,
the first centesimal (1c) dilution is obtained by dissolvingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and then subjecting it to vigorous shaking (succussion or
“dynamization”). Subsequent c dilutions are prepared by
repeating the same procedure. Although the lower dilu-
tions (i.e., 2c to 5c) contain substantial amount of the
original active phytochemical substances, their concentra-
tion progressively decreases as the number of dilutions
increases. Thus, in order to address possible mechanisms
of action of high dilutions, physical or chemical mecha-
nisms involving changes imparted to the solvent itself
have been hypothesized [21-23]. This is a fairly controver-
sial question in the literature on Gelsemium s., since most
authors have investigated only a narrow range of doses or
dilutions. It is also important, when dealing with elusive
phenomena such as biological responses to diluted and
dynamized substances, to take special care with the
controls: the recent consensus recommendation among
researchers in this field is for protocols that use the
diluted and succussed vehicle solution as a control,
however this is still a debated theme and has been done
only in few cases [24,25].
Previous investigations in our laboratory [26,27] have
shown a significant anxiolytic-like activity of Gelsemium
s. high dilutions (namely 5c, 7c, 9c and 30c according to
different test paradigms) in mice, using emotional re-
sponse models. Other laboratories have also reported
in vivo [16,19,28,29] or in vitro [30] effects of Gelsemium
s. in extremely low doses or high dilution/dynamization,
but its action at the cellular level has not been fully clari-
fied. To follow up the above evidence of an anxiolytic
effect in animal models, we decided to investigate the
Gelsemium s. mechanism of action in neuronal models
by assessing the drug effects on whole genome expres-
sion changes. The SH-SY5Y and IMR-32 human neuro-
blastoma cells were used since are widely employed in
neuropharmacology [31-33]. Finally, this approach allowed
us to test several replications of multiple doses and dilu-
tions of the remedy, taking advantage of high-throughput
and easily reproducible microarray technology.
Cells were treated with a wide variety of doses: in total,
we tested 6 increasing dilutions - which was the maximum
sample size permitted by technical constraints - from the
low dilution 2c (dilution factor 104) to the extremely high
dilution 30c (dilution factor 1060). The 5c, 9c, 30c dilu-
tions are among the most frequently used drug formu-
lations in complementary therapies on humans [34].
The drug effects were compared with those of the same
solvent used for the dilutions of Gelsemium s., just
without the plant extract (control solutions). After test-
ing for possible toxic effects of any dilution on cell via-
bility, their effectiveness in changing gene expression
was evaluated using a microarray designed for the
whole human transcriptome. Gelsemium s. 2c was
checked in SH-SY5Y and IMR-32 cells and the mostresponsive cell line was chosen for testing also higher
dilutions/dynamizations.
Methods
Preparation of Gelsemium s. and control solutions
The homeopathic dilutions/dynamizations were prepared
in a manner comparable to methods used by commercial
manufacturers, i.e. using 30% ethanol for all dilution/
succussion steps. Since ethanol at higher concentration
may be toxic for cells the 100x, last dilution/succussion
was made in pure water. The detailed procedure was
carefully repeated in all experiments and precisely re-
ported below, since it is relevant as basic science research
on homeopathic medicine progresses. Whole hydroalco-
holic extract (MT) of Gelsemium s. was produced by
Boiron Laboratoires, Lyon (F) according to the French
Homeopathic Pharmacopoeia [35]. The gelsemine content
in the MT was 6.5 × 10−4 M. MT was diluted 100 times in
30% ethanol/distilled water to obtain the 1c dilution. Sub-
sequent serial 100× dilutions up to 29c, each followed by
vigorous succussion (shaking) were then prepared in the
same solvent using glass bottles. 30-ml bottles containing
1c, 2c, 3c, 4c, 8c and 29c dilutions were supplied by the
manufacturer wrapped in aluminum foil and stored in the
dark at room temperature in a metal cupboard. The con-
trol solutions (solvent) were prepared as the drug dilutions
just without the plant extract. The 1c, 2c, 3c, 4c, 8c and
29c solvent samples contain only 30% ethanol/distilled
water, but differ for the number of succussions performed.
To prepare the final dilutions used in the tests, immedi-
ately before the experiments, 0.05 ml of the solutions
(Gelsemium s. and controls) were added to 4.95 ml of dis-
tilled sterile-filtered water (Sigma-Aldrich) in a sterile
15 ml Falcon polystyrene plastic tube and shaken in a
DinaA mechanical shaker for 7.5 sec (150 strokes). This
yielded the 2c, 3c, 4c, 5c, 9c and 30c succussed dilutions,
with ethanol concentration lowered to 0.3% (v/v) (final
0.03% in the assay system).
UV-visible absorption spectra of Gelsemium s. samples
were performed with a Jasco V550 double-beam spectro-
photometer using quartz cuvettes with 1-cm optical path
and control solutions as the reference samples.
Exposure of cells to Gelsemium s. and control dilutions
Human neuroblastoma cell line SH-SY5Y [36,37], kindly
provided by prof. Ubaldo Armato (Department of Life and
Reproduction Sciences, University of Verona), was grown
in DMEM-F12 (1:1) medium (Lonza, Walkersville, MD,
USA), supplemented with 10% foetal bovine serum (FBS;
Lonza), penicillin (100 units ml−1) and streptomycin
(100 mg ml−1) (Lonza). The culture medium was replaced
every three days. The cells were grown in Greiner plastic
culture flasks at 37°C in a 5% CO2 atmosphere, until 80%
confluence was reached. Cells were propagated after
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and then used for the gene expression assay. Cells were
counted in duplicate in a Thoma counting chamber after
staining with Turk blue reagent. For the analysis of differ-
ential gene expression, SH-SY5Y cells were plated onto
Petri dishes (Ø 100 mm) and, the day after this plating,
the culture medium was replaced with the same medium
(10 ml) supplemented with 2% FBS. After 24 h, 1 ml of
Gelsemium s. or control dilution was added to the cell cul-
ture and maintained at 37°C with 5% CO2 in a humidified
atmosphere (90% humidity) for a further 24 h. Four repli-
cate experiments were carried out under identical condi-
tions. In three experiments, Gelsemium s. 2c and the
respective control were tested on IMR-32 neuroblastoma
cell line (CCL-127 purchased from ATCC, Manassas, VA,
USA), grown and treated under the same conditions,
except that EMEM medium (Lonza) was used instead of
DMEM-F12.
Cell viability assay
The cytotoxic action of the Gelsemium s. or ethanol
dilutions on SH-SY5Y cells was assessed by the
WST-1 assay [38]. In this test, cell viability is
reflected by mitochondrial dehydrogenase activity in cleav-
ing tetrazolium salts (WST-1 reagent, Roche Molecular
Biochemicals -Mannheim, Germany) to soluble formazan.
A total of 20,000 cells per well were seeded in a 96-well
microplate in the DMEM-F12 medium with 10% FBS and
left to adhere for 16 h. Then the culture medium was
replaced with 200 μl of the same medium supple-
mented with 2% FBS. Drug and control solutions
(22 μl) were then added (6 replicates of each condition
for each plate) and the plate was incubated at 37°C in a
5% CO2 atmosphere. After 24 h, 1:10 (v/v) pre-warmed
WST-1 solution was added to the cells and the plate incu-
bated for 3 h. The absorbance (OD) of the samples was
measured using a Victor3 multilabel reader (PerkinElmer,
Shelton, CT, USA ) at 450 nm, and cell metabolic activity
was evaluated as the difference between OD at 3 h and
OD at T0.
Measurement of intracellular Ca2+ concentration
Increase in intracellular Ca2+ was monitored as described
[39] with minor modifications. SH-SY5Y cells were inocu-
lated in 96-well black microplates (flat transparent bot-
tom) with a density of 80,000 cells/well and left to adhere
for 16 h. The culture medium was removed from the
wells, and the cells were washed with warm Hank’s basal
saline solution (HBSS, Sigma-Aldrich) with 20 mM Hepes
(Sigma-Aldrich) and incubated with loading medium
(100 μl/well) at 37°C for 40 min in the dark, with 5% CO2
in a humidified atmosphere. The loading medium was
made up of the Ca2+-sensitive dye Fluo-4 AM (4.5 μM)
(Invitrogen, Paisley, UK) and probenecid (2.5 mM)(Invitrogen) in HBSS. After incubation, the cells were
washed and incubated with warm HBSS containing
2.5 mM probenecid at 37°C for 30 min in the dark. At
the indicated time, carbachol (Sigma-Aldrich) was
added at the final concentrations of 1, 5, 10, 20 μM
and the plate was transferred to a Victor3 multilabel
reader (PerkinElmer) for the measurements. Each dose
was measured in triplicate and compared with a blank
for about 15 min using the kinetic mode.
RNA isolation and quality controls
Cells exposed to 24 h Gelsemium s. or control solutions
were harvested with trypsin-EDTA-PBS treatment
(5 mg L−1, Lonza) and counted. Then, total RNA was
promptly extracted (from 3.5 × 106 cells) using the Qiagen
RNAeasy Mini Kit (Qiagen GmbH, Hilden, Germany) fol-
lowing the manufacturer’s instructions (Animal cells Spin
protocol), including genomic DNA elimination step in
column. RNA extraction was performed within 20 min
from cell detachment. The RNA samples were concen-
trated by precipitation with 2.5 volumes of ice-cold abso-
lute ethanol in presence of 0.3 M Na acetate. RNA yield
was determined by a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA) and RNA in-
tegrity was then evaluated using the 2100 Bioanalyzer
(Agilent, Santa Clara, CA, USA).
cDNA synthesis, labelling and microarray hybridisation
Microarray analysis was performed on a 12 × 135 K (i.e.
made with 12 sub-arrays and 135,000 probes per sub-array)
human NimbleGen microarray chip (Roche NimbleGen,
Madison, WI, USA, catalogue no. 05 543 789 001, design
100718_HG18_opt_expr_HX12) containing 45033 genes
with 3 probes per target gene. The microarray is based
on HG18, Build 36; cDNA synthesis, labelling and
hybridization were performed according to manufacturer’s
protocols (http://www.nimblegen.com/support/dna-micro-
array-support.html; see file 05434505001_NG_Expression_U-
Guide_v6p0.pdf). Briefly, 10 μg total RNA for each sample
was used to synthesize cDNA using a SuperScript double-
strandedcDNA synthesis kit (Invitrogen) with oligo(dT)
primers for amplification. After further evaluation of
integrity and yield with the Bioanalyzer, the cDNA samples
were labelled with Cy3 using a NimbleGen One-Color DNA
labelling kit (Roche). 4 μg of Cy3-cDNA were hybridized on
each subarray for 16 h at 42°C. All 12 samples (6 Gelsemium
s. and 6 controls) for each experiment were hybridized in the
same chip and processed simultaneously. Sample tracking
controls were used to ensure against cross contaminations
or erroneous loading in the array. The procedure was
repeated for four and three biological replicates with SH-
SY5Y and IMR-32 cells, respectively.
The arrays were scanned with a GenePix 4400A scan-
ner (Molecular Devices Corp., Sunnyvale, CA, USA) and
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the NimbleScan software for grid alignment and expres-
sion data analysis. Quality control of the array images
was performed on the basis of the parameters reported
in the Experimental Metrics Report as indicated by the
NimbleGen Software Guide v3.0. The parameters assessed
the absence of spatial biases of the fluorescence within
each subarray, the homogeneity of the mean signal among
the subarrays and the acceptable level of background
(empty and random spots) before background correction
and intra-array normalization. Gene calls were generated
using the Robust Multichip Average (RMA) algorithm
as described by Irizarry et al. [39]. Normalization was
performed using quantile normalization as described by
Bolstad et al. [40]. The data have been deposited in
NCBI's Gene Expression Omnibus [41] and are access-
ible through GEO Series accession number GSE42236.
Real time quantitative RT-PCR
A qRT-PCR analysis was performed on SH-SY5Y neuro-
blastoma treated with Gelsemium s. 2c or the control 2c,
to verify the gene expression profile of AIPL1, ALPK3,
BIRC8, C1ORF167, DDl1, EN2, GALR2, GPR25, LST1,
OR4X1, OR5C1, KLKBL4 and TAC4 genes, that were
identified by microarray analysis. UPL hydrolysis probes
and primers (RealTime ready Assays, Roche) were spe-
cifically designed and experimentally validated to match
the differentially expressed transcript Id identified by
Nimblegen microarray. One μg of RNA previously
extracted (Qiagen), quantified spectrophotometrically
(Nanodrop) and further DNase treated (Turbo DNA-free
kit, Ambion), was reverse transcribed using Transcriptor
First Strand Synthesis kit with oligo dT (Roche) and sub-
sequently 250 ng of cDNA were pre-amplified with a pool
of primers following the instruction of RealTime Ready
cDNA Pre-Amp Master kit (Roche). The pool consisted of
the RealTime Ready Assays primers specific for genes
listed above diluted 1:10 each in water PCR-grade. One to
20 diluted pre-amplified cDNA was put in qPCR with the
gene specific RealTime Ready Assays and with FastStart
Universal Probe Master-Rox (Roche). Briefly, the reaction
mixture consisted of 10 μl of 2X FastStart Universal Probe
Master-Rox, 1 μl of 20X RealTime ready Assay, 1 μl of
template cDNA diluted 1:10 and nuclease free water up to
20 μl. Three different technical replicates were analyzed
for each cDNA sample in the same assay and β–actin
(ACTB gene ID: 60) and β-2 microglobulin (B2M gene
ID: 567) were used as housekeeping genes for the
normalization. The StepOne Plus Real-time PCR System
(Applied Biosystem, USA) was used to monitor the hy-
drolysis probe signal generated with a standard thermal
profile specific for this kind of probe, i.e.10 min of 95°C,
followed by 40 cycles of 95°C 15 sec, 1 min of 60°C. The
quantification cycle (Cq) was determined by using the logview of the ΔRn amplification plots, normalized by the in-
ternal ROX reference dye, whereas the relative fold change
(FC) in the expression levels was determined with the
ΔΔCq method, taking the mean of the three PCR repli-
cates. Data are presented as Log2 transformation of FC.
Statistics
The experimental model had dose–response setup, in-
cluding 6 dilutions of Gelsemium s. and 6 corresponding
controls. The main working variable was the Log2-
transformed fluorescence value of microarray analysis of
gene expression. Data from 4 independent experiments
were considered. Expecting effects to diminish with in-
creasing dilution, we focused to a pair-wise comparison
between Gelsemium s. dilutions and the vehicle controls
instead of an overall comparison analysis. Two consecu-
tive statistical approaches were followed. The first ap-
proach analyzed the complete transcriptome dataset and
was aimed to select the DEGs that were most signifi-
cantly affected by treatment at the highest dose; linear
model (Limma) was applied to compare the expression
values from Gelsemium 2c treated and the mean of con-
trols (see details below). The second approach analyzed
only the expression values of the selected DEGs when
treated with highly diluted drugs or the corresponding
controls. The main focus was to verify the null hypoth-
esis that the higher Gelsemium s. dilutions did not affect
the expression of the genes compared to control. For
this analysis we used Friedman test as nonparametric
ANOVA and Fisher’s exact test (see details below). The
tests analyzed the distributions of the fold changes in
the down- or up-regulated DEGs and determined whether
the direction of effect for the DEGs detected in the 2c
concentration was maintained across all other dilu-
tions (3c-30c).
In the first part of analysis, a linear modelling ap-
proach and the empirical Bayes statistics as implemented
in the Limma package [42] were employed for differen-
tial expression analysis. The Limma test was applied to
compare Gelsemium s. dilutions with controls, or controls
between each other. The p-values were adjusted for the
False Discovery Rate (FDR) on the 45033 cases using the
Benjamini and Hochberg method [43]. No pre-filtering to
the dataset (variant-based or minimal expression-based)
was applied to avoid a-priori loss of results when studying
minimal doses of drug. Log2 fold change was calculated as
Log2-transformed fluorescence value of Gelsemium s. di-
lutions minus Log2-transformed fluorescence value of
mean of controls. DEGs were selected as significant and
interesting for further analysis if their absolute value of
Log2 fold change (|log2 fold change|) was higher than 0.5
and the adjusted p-value was <0.05.
In the second part of the analysis, the significant DEGs
in 2c treatment were divided in two groups (considered
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cluding down- and up-regulated genes; data referred to
the same dilution (from 2c to 30c of both treatments
and respective controls) were joined, treating the single
gene as a statistical unit and the mean of four replica-
tions as the corresponding datum. Statistical significance
of the overall differences between expression profiles of
gene-sets (down- and up-regulated) in various treatment
conditions was calculated by the Friedman multi-sample
test using SPSS software, version 17 (SPSS Inc., Chicago,
IL, USA). The Friedman test is a nonparametric test for
multiple related samples (in our case, the expression
level of multiple matched samples from cells treated
with 6 Gelsemium s. dilutions or 6 control solutions)
that checks the null hypothesis that multiple ordinal re-
sponses come from the same population. Following a
significant result of Friedman test, frequency of down-
regulated vs upregulated genes were calculated; |log2
fold change| lower than or equal to 0.05 were considered
to be null. The significance of distributions for each dilu-
tion was analyzed by the Fisher’s exact test, which calcu-
lates the exact probability of getting, only by chance, the
observed values or more extreme ones. A randomly
selected set of 49 genes, for comparison of frequency
of down-regulated vs up-regulated genes with the
Gelsemium s.-specific gene-set, was generated from the
whole microarray dataset, using the specific function of
the SPSS 17 software.
Gene expression profiles were clustered by the k-means
clustering method and Pearson correlation metrics using
the MeV 4.8.1 software (http://www.tm4.org/mev.html).
The application “Figure of merit” (FOM) was used to set
the number of clusters that best fit the dataset variability
[44]. The FOM measures the average intra-cluster vari-
ance of the observations, estimating the mean error using
predictions based on the cluster averages [45]. Gene func-
tional classification and enrichment analysis were per-
formed by DAVID Bioinformatics Resources 6.7 (http://
david.abcc.ncifcrf.gov) [46]. Results of viability assay were
analyzed by ANOVA and t-test comparing data from
each Gelsemium s. dilution (G2c, G3c, G4c, G5c,
G9c and G30c) with the corresponding controls (n =
12 replicates for each group).
Results
Cell morphology and function
The SH-SY5Y neuroblastoma cells used in the assay
exhibited a neuron-like shape with visible axons and
junctions when grown in Petri dishes (Figure 1A). To
assess the basal neuronal reactivity of these cells, the
culture was stimulated with different doses of the
acetylcholine-analogue carbachol and the change in con-
centration of intracellular calcium was measured with the
Ca2+-sensitive probe Fluo4-AM. As shown in Figure 1B,the cells were sensitive to the varying amounts of the
neurotransmitter, and intracellular calcium concentration
increased in a dose-dependent way.
UV–VIS Spectra of Gelsemium s.
Figure 2 shows the absorption spectra of some of the
preparations used in this study. The spectrum of the
lowest dilution (1c) was considered as marker for the
actual presence of plant extract. Spectra of the subse-
quent dilutions checked the effectiveness of the 100 ×
dilution steps, i.e. verified that a) the lower dilutions
(from pharmaceutical factory and prepared in the la-
boratory) were comparable and b) the provided higher
potencies were effectively diluted. The original 1c dilu-
tion supplied by the factory (panel A) was characterized
by high absorption in UV region near 210 nm and by
two absorption shoulders at 280 nm and 330 nm; no ab-
sorption in the visible spectrum region above 450 nm
was detected. The original 2c dilution (panel B) showed
a qualitatively similar spectrum, but with an absorption
intensity about 100 times lower than that of 1c, indicat-
ing that the dilution was done correctly during the
preparation process. The 3c dilution (panel C) has no
significant absorption over the background noise level,
which is as expected since it was produced by a 100 × dilu-
tion of 2c. The 2c solution prepared in the laboratory
by a 100 × dilution of the original 1c in water (panel D)
shows a spectrum with absorption features corresponding
roughly to 1/100 of the spectrum of (panel A), indicating
that the final dilution of the samples for use in cell assays
was done correctly. The spectra of higher dilutions
were below the detection limit for this technique (data
not shown).
Effect of Gelsemium s. dilutions on SH-SY5Y viability
To evaluate whether the Gelsemium s. dilutions had any
toxic effects, the viability of SH-SY5Y cells after expos-
ure to drug dilutions for 24 h was checked by WST-1
spectrophotometric assay. As can be seen in Figure 3,
Gelsemium s. dilutions did not impair cell viability as
compared to controls. No significant differences in cell
viability were observed between cells treated with the
ethanol control solution 0.03% (v/v) and untreated cells
(data not shown).
Gene expression changes induced in SH-SY5Y cells
Global changes in gene expression produced by exposure
to low doses or high dilutions of Gelsemium s. extracts in
human SH-SY5Y neuroblastoma cells were investigated by
microarray analysis, and the results selectively compared
with the gene expression of cultures exposed to the ve-
hicle solutions. Cells were incubated for 24 h with the 6
dilutions of Gelsemium s. or the corresponding controls,
after which the 12 samples were rapidly processed and
Figure 1 Morphological and functional properties of SH-SY5Y neuroblastoma cells used in the assay. A. Phase contrast micrograph of
adherent cells cultured in Petri dishes. Bar, 10 μm. B. Spectrofluorometric measurement of intracellular calcium changes induced by carbachol at
the specified doses.
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After running a total of 4 experiments, differential gene
expression was analyzed. The general correlation values
among the 48 normalized sub-arrays compared in the
analysis (12 conditions and 4 replicates) was very high
(Pearson correlation coefficient >97%, mean = 0.988), dem-
onstrating the reproducibility of the experiments.
Preliminary Limma analysis, performed only with the
control samples, excluded the presence of significantFigure 2 UV–vis spectra of representative Gelsemium s. solutions. A: G
2c dilution supplied, C: Gelsemium s. 3c dilution supplied, D: Gelsemium s. 2
the experiments.differences among the different diluted/succussed vehi-
cles (adjusted p > 0.05), and authorized merging them in
a unique control group. The difference in expression
(Log2 fold change) between Gelsemium s. and the aver-
age of the controls was calculated for each dosage, and
the results were compared to detect any trend in the re-
sponse to increasing drug dilutions. In general, the range
of changes in gene expression was quite narrow: out of a
total of 45033 transcripts, in Gelsemium s. 2c and 3c,elsemium s. 1c dilution supplied by the manufacturer, B: Gelsemium s.
c dilution prepared by 100 × dilution of solution A and used in
Figure 3 Effects of Gelsemium s. on SH-SY5Y cell viability. Cell viability was determined by WST assay after 24 h treatment with Gelsemium s.
or Control dilutions. Values in abscissa are mean absorbance values ± SD (n = 6).
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and 165, respectively) showed |log2 fold change| > 0.5.
Among these DEGs, exposure to Gelsemium s. 2c pro-
moted a statistically significant down-expression of 49
genes, while 7 genes were overexpressed (Limma ana-
lysis with adjusted p < 0.05) (Table 1). In general, mean
fold changes in the mRNAs levels of cells treated with
Gelsemium s. were small and only 4 genes showed |log2
fold change| > 0.8. No significant changes of housekeep-
ing genes were recorded, as expected.
Gene expression changes induced in IMR-32 cells
To verify whether the effect of Gelsemium s. could
be reproducible in different types of neurocytes, the
Gelsemium s. 2c treatment and the corresponding etha-
nol controls were applied to the IMR-32 human neuro-
blastoma cell line. After three replicate experiments, the
analysis did not detect significant changes between
Gelsemium s. and controls if the cut-off values of |log2
fold change| > 0.5 and adjusted p < 0.05 (Limma analysis
with Benjamini and Hochberg correction) were applied.
As observed in the SH-SY5Y cells, the global gene expres-
sion change in the IMR-32 cells was slight, since only 116
genes (0.25% of the transcripts) registered |log2 fold
change| >0.5 (compared to the 577 genes in SH-SY5Y
cells, corresponding to 1.3% of total). In any case, as
shown in Figure 4, the changes in the 56 selected genes of
SH-SY5Y cells were in the same direction in the IMR32
cells. In fact, 44 of the 49 genes that were down-regulated
in SH-SY5Y also had a negative fold change in IMR-32,
and 6 of the 7 genes that were up-regulated in SH-SY5Y
also had a positive fold change in IMR-32. These datashow that the expression of the same gene-set was also
modified in a second type of neurocyte, although the most
sensitive model for detecting the effect of Gelsemium s. is
the SH-SY5Y cell line.
Real time quantitative PCR: Validation of the
microarray data
To validate the microarray results, RT-qPCR analysis was
performed on SH-SY5Y cells exposed to the Gelsemium s.
2c and the corresponding control. RT-PCR was carried out
on the cDNA obtained from the RNA samples of 3 replicate
experiments tested by microarray assay. Among the list of
DEGs (see Table 1) we selected 13 genes according to the
extent of expression changes and their potential relevant
functions (e.g. transcription factors, G-protein coupled re-
ceptors or neuropeptides) (Table 2). The genes investigated
by quantitative PCR generally confirmed the changes
obtained by microarray assay. DDI1, EN2, GALR2,
GPR25, OR5C1, Klkbl4 and TAC4 genes were down-
regulated in Gelsemium s. 2c samples compared to Con-
trol 2c in the three replicated experiments. Negative fold
changes were observed also with BIRC8 genes, although
with variable values. The applied RT-qPCR assays could
not detect AIPL1, C1orf167, LST1 and OR4X1, because
their expression was under the sensitivity of the assay,
and did not confirm the up-regulation of ALK3 gene.
Statistical analysis of data from Gelsemium s. dilutions
and controls
SH-SY5Y cells treated with higher Gelsemium s. dilu-
tions (3c, 4c, 5c, 9c, 30c) showed changes in gene ex-
pression due to treatment, which were rated by Limma
Table 1 Differentially expressed genes after treatment with Gelsemium s. 2c in SH-SY5Y cells
Gene ID Transcript ID Symbol Log2 fold change p1 Description
7940 AF000424 LST1 −0.84 ± 0.14 0.04 Leukocyte specific transcript 1
390113 NM_001004726 OR4X1 −0.83 ± 0.06 0.01 Olfactory receptor, family 4, subfamily X, member 1
23746 AJ830742 AIPL1 −0.82 ± 0.16 0.04 Aryl hydrocarbon receptor interacting protein-like 1
284498 AL833920 C1orf167 −0.80 ± 0.17 0.05 Chromosome 1 open reading frame 167
221191 AK058068 Klkbl4 −0.79 ± 0.12 0.04 Plasma kallikrein-like protein 4
26658 NM_012377 OR7C2 −0.77 ± 0.07 0.01 Olfactory receptor, family 7, subfamily C, member 2
112401 BC039318 BIRC8 −0.76 ± 0.11 0.00 Baculoviral IAP repeat-containing 8
2848 NM_005298 GPR25 −0.75 ± 0.15 0.02 G protein-coupled receptor 25
55803 NM_018404 ADAP2 −0.75 ± 0.11 0.02 ArfGAP with dual PH domains 2
386676 NM_198690 KRTAP10-9 −0.73 ± 0.12 0.04 Keratin associated protein 10-9
4353 X04876 MPO −0.72 ± 0.15 0.04 Myeloperoxidase
N/A AY358413 N/A −0.71 ± 0.18 0.02 Homo sapiens clone DNA59853 trypsin inhibitor
392391 NM_001001923 OR5C1 −0.71 ± 0.05 0.04 Olfactory receptor, family 5, subfamily C, member 1
N/A AK094115 N/A −0.70 ± 0.11 0.04 Homo sapiens cDNA FLJ36796 fis, clone ADRGL2006817
55287 BC020658 TMEM40 −0.70 ± 0.15 0.02 Transmembrane protein 40
54209 NM_018965 TREM2 −0.69 ± 0.10 0.02 Triggering receptor expressed on myeloid cells 2
150365 AK097834 RP5-821D11.2 −0.68 ± 0.17 0.02 Similar to mouse meiosis defective 1 gene
400934 NM_207478 FLJ44385 −0.68 ± 0.09 0.04 FLJ44385 protein
255061 NM_170685 TAC4 −0.67 ± 0.14 0.01 Tachykinin 4 (hemokinin)
644065 XM_931993 LOC644065 −0.65 ± 0.23 0.04 Hypothetical protein LOC644065
1339 NM_005205 COX6A2 −0.64 ± 0.17 0.01 Cytochrome c oxidase subunit VIa polypeptide 2
N/A AK128093 N/A −0.63 ± 0.09 0.04 Homo sapiens cDNA FLJ46214 fis, clone TESTI4012623.
53841 AY358368 CDHR5 −0.63 ± 0.11 0.04 Mucin-like protocadherin
9332 NM_004244 CD163 −0.63 ± 0.18 0.03 CD163 molecule
441239 XM_499305 LOC441239 −0.63 ± 0.22 0.05 Hypothetical gene supported by BC063653
7164 NM_001003397 TPD52L1 −0.62 ± 0.09 0.02 Tumor protein D52-like 1
11136 NM_014270 SLC7A9 −0.62 ± 0.09 0.04 Solute carrier family 7 member 9
389084 NM_206895 UNQ830 −0.62 ± 0.11 0.04 ASCL830
400224 XM_375090 FLJ44817 −0.62 ± 0.20 0.04 Similar to pleckstrin homology domain protein (5 V327)
647240 XM_934559 LOC647240 −0.60 ± 0.06 0.00 Hypothetical protein LOC647240
846 BC104999 CASR −0.59 ± 0.06 0.00 Calcium-sensing receptor
116123 NM_138784 RP11-45 J16.2 −0.58 ± 0.09 0.04 Flavin-containing monooxygenase pseudogene
644280 XM_497769 LOC644280 −0.58 ± 0.06 0.05 Hypothetical protein LOC644280
57452 AB032956 GALNTL1 −0.57 ± 0.17 0.05 Alpha-D-galactosamine N-acetylgalactosaminyltransferase
414301 NM_001001711 DDI1 −0.56 ± 0.11 0.04 DDI1, DNA-damage inducible 1, homolog 1 (S. cerevisiae)
116535 BC016964 MRGPRF −0.55 ± 0.17 0.01 MAS-related GPR, member F
8811 NM_003857 GALR2 −0.55 ± 0.07 0.04 Galanin receptor 2
10880 NM_006686 ACTL7B −0.55 ± 0.12 0.04 Actin-like 7B
6368 NM_145898 CCL23 −0.55 ± 0.11 0.05 Chemokine (C-C motif) ligand 23
64581 BC071746 CLEC7A −0.54 ± 0.08 0.04 C-type lectin domain family 7, member A
644003 XM_927256 LOC644003 −0.54 ± 0.11 0.04 Similar to Mucin-2 precursor (Intestinal mucin 2)
643514 XM_931594 LOC643514 −0.54 ± 0.10 0.03 Hypothetical protein LOC643514
374569 XM_935431 LOC374569 −0.54 ± 0.07 0.04 Similar to Lysophospholipase
84504 BC101635 NKX6-2 −0.53 ± 0.13 0.03 NK6 transcription factor related, locus 2 (Drosophila)
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Table 1 Differentially expressed genes after treatment with Gelsemium s. 2c in SH-SY5Y cells (Continued)
732 NM_000066 C8B −0.53 ± 0.06 0.05 Complement component 8, beta polypeptide
146336 NM_182510 FLJ32252 −0.52 ± 0.03 0.01 Hypothetical protein FLJ32252
150763 BC042847 LOC150763 −0.51 ± 0.10 0.04 Hypothetical protein LOC150763
2020 NM_001427 EN2 −0.51 ± 0.08 0.04 Engrailed homolog 2
646258 XM_929203 LOC646258 −0.51 ± 0.11 0.04 Hypothetical protein LOC646258
154872 NM_001024603 LOC154872 0.51 ± 0.10 0.03 Hypothetical LOC154872
400866 NM_001001789 C21orf24 0.52 ± 0.12 0.05 Chromosome 21 open reading frame 24
9457 NM_020482 FHL5 0.55 ± 0.19 0.04 Four and a half LIM domains 5
55816 NM_018431 DOK5 0.56 ± 0.04 0.03 Docking protein 5
1446 NM_001890 CSN1S1 0.57 ± 0.09 0.04 Casein alpha s1
285600 AK130941 KIAA0825 0.63 ± 0.06 0.01 KIAA0825 protein
57538 NM_020778 ALPK3 0.76 ± 0.10 0.01 Alpha-kinase 3
The table includes the genes with absolute Log2 fold change higher than 0.5. Each gene is described via GeneBank accession number (Gene ID), Gene symbol
(Symbol), NimbleGen array transcript designation (Transcript ID). The log2 fold change of expression compared to mean control vehicle-treated cells is displayed
as mean ± SEM (n = 4 replicate experiments). 1adjusted p value with Benjamini-Hochberg correction, obtained by Limma statistical test.
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ported in Table 3, concerning the expression profiles of
the 56 DEGs (49 down-regulated and 7 up-regulated by
Gelsemium s. 2c), highlights small expression changes
(i.e. |log2 fold change| from 0.05 to 0.6) in 52, 48, 39, 36
and 48 genes of cells treated with Gelsemium s. 3c, 4c,
5c, 9c and 30c respectively. In order to analyze theFigure 4 Differential effect of Gelsemium s. on two cell lines. Fold chan
cells after 24 h treatment with Gelsemium s. 2c.statistical significance of these effects, a further ap-
proach was applied to these 56 DEGs. The hypothesis
tested was to determine whether treated samples were
different from controls or not and, in particular, if the
direction of DEGs’ changes detected in the 2c was
maintained across all other dilutions rather than ran-
domly distributed.ges of the 56 selected genes in SH-SY5Y (red bars) and IMR32 (blue bars)
Table 2 Validation of microarray data of selected genes by RT-qPCR in Gelsemium s. 2c versus Control 2c treated samples
Fold change microarray1 Fold change RT-PCR2
Symbol Gene ID R1 R2 R3 Mean SEM R1 R2 R3 Mean SEM
AIPL1 23746 −0.60 −0.59 −1.06 −0.75 0.13 n.d. n.d. n.d.
ALPK3 57538 1.16 0.04 0.96 0.72 0.28 −0.87 0.24 −0.25 −0.29 0.26
BIRC8 112401 −0.79 −0.77 −0.91 −0.82 0.04 1.64 −1.12 −1.43 −0.30 0.80
C1ORF167 284498 −0.69 −0.51 −1.00 −0.73 0.12 n.d. n.d. n.d.
DDI1 414301 −0.93 0.02 −1.30 −0.74 0.32 −0.62 0.16 −1.23 −0.56 0.33
EN2 2020 −0.62 −0.13 −0.77 −0.51 0.16 −1.53 −0.12 −0.41 −0.69 0.35
GALR2 8811 −0.57 −0.36 −0.72 −0.55 0.08 −0.94 −0.19 −0.61 −0.58 0.18
GPR25 2848 −1.15 0.20 −1.08 −0.68 0.36 −0.74 0.60 −0.11 −0.08 0.32
LST1 221191 −0.71 −0.76 −1.18 −0.88 0.12 n.d. n.d. n.d.
OR4X1 7940 −0.96 −0.55 −0.74 −0.75 0.10 n.d. n.d. n.d.
OR5C1 390113 −0.84 −0.33 −0.79 −0.66 0.13 −0.95 −0.51 −1.00 −0.82 0.13
Klkbl4 392391 −0.05 −0.70 −1.04 −0.60 0.24 −1.10 −0.17 −0.41 −0.56 0.23
TAC4 255061 −0.23 −0.28 −1.34 −0.62 0.30 −1.14 −0.10 −0.46 −0.57 0.25
1Fold change was calculated as Log2 ratio between G2c and Ct2c expression values within the three replicated experiments (R1-R3); 2fold change was calculated
as Log2 transformation of 2-ΔΔCq between G2c and Ct2c. N.d., not detectable.
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Expression values (mean of 4 experiments) of the 49
down- and 7up-regulated genes referred to the same
dilution (2c ÷ 30c) of treatments and respective controls
were compared. Additional file 1 reports Log2 data of all
samples tested in this analysis. Friedman test estimated
the overall variance among the samples and showed that
the value distributions of the 12 different treatment
groups (6 Gelsemium s. and 6 controls, n = 49 or n = 7
data for down-regulated and up-regulated genes, respect-
ively) are significantly different (p < 0.0001). For a direct
evaluation of the differences between Gelsemium s. treat-
ments and the corresponding controls, Figure 5 shows the
distribution of the fold changes in the 49 down-regulated
genes for all the dilutions tested. Even though the size
of the differences was distributed in a small range,
the number of genes with negative fold change (Log2
Gelsemium s. < Log2 control, blue in Figure 5) was
systematically higher than the number of genes with
positive fold change (Log2 Gelsemium s. > Log2 con-
trol, pink bars in Figure 5). In particular, the frequency
of down-regulated vs up-regulated genes was 49 vs. 0
(100% vs. 0%) in 2c, as expected, 47 vs. 2 (96% vs. 4%)
in 3c, 42 vs. 3 (86% vs. 6%) in 4c, 38 vs. 3 (78% vs. 6%)
in 5c, 30 vs. 9 (61% vs. 18%) in 9c, 27 vs 7 (55% vs. 14%) in
30c. By applying Fisher exact test, the exact probability of
the distributions, under the null hypothesis of indifference,
was calculated and significant p values resulted for all di-
lutions (p < 0.001 for 3c, 4c and 5c treatments, p = 0.0035
for 9c and p = 0.004 for 30c). The absence of an equal
scattering between the two signs (positive and negative
fold changes) suggests that Gelsemium s. at high dilutions
affects the expression of a significant portion of thesegenes. This conclusion is reinforced by a separate Fisher
exact test carried out on a list of 49 genes randomly se-
lected by the SPSS software from the 45033 transcripts
(excluding the 56 DEGs); as reported in Additional file 2,
no significantly different distribution of down-regulated or
up-regulated genes in this random gene-set was observed
with any Gelsemium s. dilution. Figure 6 reports the re-
sults for the panel of 7 up-regulated genes. Due to the
small number of these genes, a distribution of fold changes
could not be drawn and the statistical power of analysis
was low. By Fisher exact test, a statistically significant
prevalence of positive fold changes was observed only
in 2c, as expected, while the prevalence of positive fold
changes in the other dilutions was not significant.
Cluster analysis
With the aim to describe the trends of gene expression
when exposed to higher Gelsemium s. dilutions, k-means
cluster analysis was applied on the Log2-fold change
profiles of the 56 selected genes. The effect of all the
tested Gelsemium s. dilutions was visualized as a heat map
(Figure 7A) and as mean fold changes in each cluster of
genes (Figure 7B). This allowed to identify gene subsets
with similar expression profiles, and to detect some trends
in the changes induced by increasing Gelsemium s. dilu-
tions. Most of the genes down-regulated in the 2c-treated
samples were also under-expressed in 3c and, to a varying
extent, even in higher dilutions. The frequency of genes
with negative fold changes was above 65% in all condi-
tions, and in the sample treated with Gelsemium s. 30c the
number of common genes that were down-regulated in all
dilutions was 20 out of 49 (41%). Cluster 1 contains 20
genes whose expression was down-regulated by the 2c
Table 3 Fold changes of the 56 differentially expressed genes and the 4 housekeeping transcripts in cells treated with
the 6 Gelsemium s. dilutions compared to means of controls
Transcript ID Symbol G 2c G 3c G 4c G 5c G 9c G 30c
AB032956 GALNTL1 −0.57 −0.20 0.16 −0.13 0.02 0.09
AF000424 LST1 −0.84 −0.18 −0.20 −0.05 −0.14 −0.23
AJ830742 AIPL1 −0.82 −0.43 −0.25 −0.24 −0.07 −0.08
AK058068 Klkbl4 −0.79 −0.41 −0.17 0.11 −0.15 −0.07
AK094115 N/A −0.70 −0.35 −0.04 −0.01 0.01 −0.41
AK097834 RP5-821D11.2 −0.68 −0.31 −0.03 −0.21 −0.01 0.01
AK128093 N/A −0.63 −0.28 −0.15 0.05 −0.19 −0.30
AL833920 C1orf167 −0.80 −0.60 0.17 −0.04 0.18 −0.22
AY358368 CDHR5 −0.63 −0.23 −0.09 −0.10 −0.19 −0.25
AY358413 N/A −0.71 −0.15 0.10 0.04 0.10 −0.28
BC016964 MRGPRF −0.55 −0.08 −0.12 −0.02 0.06 0.07
BC020658 TMEM40 −0.70 −0.56 −0.15 −0.15 0.04 −0.12
BC039318 BIRC8 −0.76 −0.42 −0.10 −0.09 0.09 −0.02
BC042847 LOC150763 −0.51 −0.29 −0.12 0.01 −0.03 −0.03
BC071746 CLEC7A −0.54 −0.32 −0.12 −0.17 0.14 0.17
BC101635 NKX6-2 −0.53 −0.56 −0.12 −0.12 −0.14 −0.12
BC104999 CASR −0.59 −0.17 −0.25 0.08 0.06 −0.30
NM_000066 C8B −0.53 −0.07 0.00 −0.07 −0.03 −0.23
NM_001001711 DDI1 −0.56 −0.21 −0.27 −0.31 −0.17 −0.26
NM_001001923 OR5C1 −0.71 −0.28 −0.22 0.08 −0.13 −0.24
NM_001003397 TPD52L1 −0.62 −0.31 −0.33 −0.18 0.04 −0.31
NM_001004726 OR4X1 −0.83 −0.34 0.07 0.03 −0.11 −0.18
NM_001427 EN2 −0.51 −0.33 −0.22 −0.06 0.02 −0.13
NM_003857 GALR2 −0.55 −0.31 −0.13 0.02 −0.01 −0.13
NM_004244 CD163 −0.63 −0.30 −0.20 −0.13 0.04 −0.25
NM_005205 COX6A2 −0.64 −0.39 −0.38 −0.07 −0.30 −0.17
NM_005298 GPR25 −0.75 −0.41 0.02 −0.05 −0.02 0.02
NM_006686 ACTL7B −0.55 −0.44 −0.13 −0.02 −0.01 −0.15
NM_012377 OR7C2 −0.77 −0.22 −0.03 −0.14 −0.14 −0.03
NM_014270 SLC7A9 −0.62 −0.16 −0.20 0.01 −0.27 −0.19
NM_018404 ADAP2 −0.75 −0.40 −0.30 −0.19 0.04 0.03
NM_018965 TREM2 −0.69 −0.34 −0.08 −0.14 0.09 −0.20
NM_138784 RP11-45 J16.2 −0.58 −0.29 0.06 −0.05 0.20 −0.17
NM_145898 CCL23 −0.55 0.03 −0.09 −0.20 0.02 −0.20
NM_170685 TAC4 −0.67 −0.30 −0.19 −0.06 −0.13 −0.24
NM_182510 FLJ32252 −0.52 −0.33 −0.26 −0.10 −0.10 0.02
NM_198690 KRTAP10-9 −0.73 −0.29 −0.10 −0.03 −0.28 −0.13
NM_206895 UNQ830 −0.62 −0.45 −0.22 −0.25 −0.10 −0.18
NM_207478 FLJ44385 −0.68 −0.12 −0.10 −0.08 −0.01 −0.26
X04876 MPO −0.72 −0.36 −0.20 0.19 −0.01 −0.16
XM_375090 FLJ44817 −0.62 −0.58 −0.16 0.00 −0.27 −0.11
XM_497769 LOC644280 −0.58 −0.19 −0.20 −0.02 −0.07 −0.05
XM_499305 LOC441239 −0.63 −0.31 −0.21 −0.08 −0.15 −0.24
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Table 3 Fold changes of the 56 differentially expressed genes and the 4 housekeeping transcripts in cells treated with
the 6 Gelsemium s. dilutions compared to means of controls (Continued)
XM_927256 LOC644003 −0.54 −0.57 −0.31 −0.19 −0.27 −0.10
XM_929203 LOC646258 −0.51 −0.20 −0.38 −0.13 −0.11 −0.08
XM_931594 LOC643514 −0.54 −0.23 −0.11 −0.01 −0.21 −0.16
XM_931993 LOC644065 −0.65 −0.29 −0.15 0.05 −0.06 −0.21
XM_934559 LOC647240 −0.60 −0.40 −0.23 −0.16 −0.08 −0.08
XM_935431 LOC374569 −0.54 −0.31 −0.14 −0.12 −0.13 −0.10
AK130941 KIAA0825 0.63 0.30 −0.07 −0.07 −0.06 0.15
NM_001001789 C21orf24 0.52 0.19 0.08 −0.01 0.00 0.21
NM_001024603 LOC154872 0.51 0.13 0.15 0.05 0.06 0.21
NM_001890 CSN1S1 0.57 −0.04 0.03 0.30 −0.07 0.11
NM_018431 DOK5 0.56 0.04 0.03 0.01 −0.02 0.31
NM_020482 FHL5 0.55 0.38 0.01 0.10 −0.02 −0.08
NM_020778 ALPK3 0.76 0.45 0.23 0.16 0.03 0.19
BC001601 GAPDH1 0.01 0.09 0.02 0.10 0.03 0.04
NM_002046 GAPDH1 0.09 −0.14 −0.02 −0.10 −0.01 0.00
BC009081 GAPDH1 0.01 −0.05 0.01 −0.04 −0.04 −0.03
NM_001101 ACTB1 −0.04 −0.05 −0.05 0.05 0.02 0.00
N = 4 experiments. 1Housekeeping transcripts.
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thus drawing a curve with asymptotic direction. Clusters 2
and 3 group together the genes also down-regulated by
the Gelsemium s. high dilutions (but on which 5c or 9c,
respectively, had no effect), while cluster 4 includes the
genes that were clearly responsive to Gelsemium s. 2c
and 3c only. Cluster 5 contains the 7 up-regulated
genes. Though significant up-regulation occurred only
with 2c, most of those genes showed a similar effect
trend in all dilutions.
Functions of the modulated genes
To obtain a functional classification, the 56 genes whose
expression changed following exposure to Gelsemium in
SH-SY5Y cells were subjected to analysis of the enriched
annotation terms associated with the list. Table 4 reports
the top enriched biological themes, particularly the GO
terms discovered in the gene list by the DAVID software.
A total of 28 genes (all down-regulated) from the list
were classified into functional-related gene groups, while
17 IDs were unmapped in the DAVID database (see
Table 1) because they have unknown functions. The
remaining genes (3 up-regulated and 8 down-regulated)
have known functions but were not rated as enriched in
the list compared to the whole human transcriptome.
The main group of functional features includes genes
coding for membrane receptors, and in particular in-
volved in G-protein coupled receptor (GPCR) transduc-
tion systems (OR4X1, CASR, OR5C1, CCL23, GPR25,
GALR2, OR7C2, MRGPRF). Among these receptors,three have specific functions in olfactory transduction,
attuned to detecting different types of stimuli including
molecular vibrations [47]. The other clusters of genes
may have a role in calcium signaling, inflammatory path-
ways, neuropeptide/receptor systems or as transcription
factors. Of particular relevance for neuronal functions is
the small but significant down-regulation of the gene
TAC4 and GALR2. The first gene codes for the neuro-
peptide hemokinin-1 an analogous of substance-P [48],
and the second for the receptor 2 of the neuropeptide
galanin. Both are involved in the complex system of
psyco-neuro-immune-endocrine axis which correlates
the emotional responses with the hormone release and
the immune functions [49,50].Discussion
Natural remedies are increasingly viewed as potentially
valuable complements to conventional drugs in integrated
treatment strategies for a number of disorders, and many
consumers use natural health products alongside prescrip-
tion medications [51]. Anxiety and depression are among
the ailments most frequently reported by patients seeking
complementary and alternative medical remedies and/or
naturopathic care [9,52,53]. Gelsemium s. is a traditional
remedy used in complementary and alternative therapies
for treating patients who exhibit neurological complaints
such as headache and anxiety-like symptoms [9,52,53],
but evidence-based clinical studies are few and with
contrasting results [53,54].
Figure 5 Frequency of fold change values in the down-regulated gene-set after Gelsemium s. treatments. In this analysis the 49 genes
whose expression was down-regulated by Gelsemium s. 2c were considered. Mean Log2 fluorescence values from Gelsemium s.-treated samples
(Gnc) and those from controls (Ctnc) were obtained from 4 microarray experiments and their difference was considered as fold change attributable to
Gelsemium s. effect (see Methods). Absolute fold changes less than or equal to 0.05 were considered null. Blue bars: frequencies of genes with negative
fold change (< −0.05); grey bars: frequency of unaffected genes (from −0.05 to 0.05); pink bars: frequencies of genes with positive fold change (> 0.05).
Fisher exact p values are reported in each panel except the G2c-Ct2c that are significant by definition.
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uses extremely small doses of various substances to
stimulate auto-regulation and self-healing processes [55].
Although some conventional physicians find such no-
tions implausible [56], use of highly diluted drugs fromhomeopathic pharmacopoeia has recently seen a world-
wide revival [57,58] and laboratory investigations are
increasing in this field [26,27], but scientific evidence of
underlying molecular mechanisms is still lacking. More-
over, the experimental approaches adopted to study
Figure 6 Number of genes modulated by Gelsemium s. dilutions in the panel of up-regulated genes. In this analysis the 7 genes whose
expression was up-regulated by Gelsemium s. 2c were considered. Differences less than or equal to 0.05 were considered null. Blue bars: number
of genes with negative fold change (< −0.05); grey bars: number of unaffected genes (from −0.05 to 0.05); pink bars: number of genes with positive
fold change (> 0.05). Fisher exact test is not significant in any dilution except in the 2c dilution that is significant by definition.
Figure 7 K-mean clustering of the genes modulated upon exposure to Gelsemium s. dilutions. The expression profile of 56 genes significantly
modulated by Gelsemium s. 2c was evaluated also upon exposure to increasing Gelsemium s. (G) dilutions. Fold change was calculated as the difference
between Log2 fluorescence values of each Gelsemium s. dilution and the mean Log2 fluorescence of the controls. Data are means of 4 replicate experiments.
A. K-mean clusters (KMC) visualized as a colour-coded heat map. The down-regulated genes (green) with similar expression profiles were grouped in 4 clus-
ters and the up-regulated genes (red) in one cluster. B. Centroid graphs of the mean fold change of genes in the 5 clusters obtained in KMC analysis.
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Table 4 Top enriched annotation terms associated with the 56 genes differentially expressed upon exposure to
Gelsemium s. 2c in SH-SY5Y cells
Category Annotation term P value Genes Fold
enrichment
SP_PIR_KEYW receptor 8.32E-11 AIPL1, OR4X1, CASR, OR5C1, GPR25,
GALR2, OR7C2, MRGPRF, CLEC7A, TREM2
3.68
GOTERM_BP_FAT GO:0007186 ~ G-protein coupled receptor
protein signalling pathway
6.60E-11 OR4X1, CASR, OR5C1, CCL23, GPR25,
GALR2, OR7C2, MRGPRF, TAC4
4.17
GOTERM_BP_FAT GO:0007166 ~ cell surface receptor linked
signal transduction
0.001 OR4X1, CASR, OR5C1, CCL23, DOK5, GPR25,
GALR2, OR7C2, MRGPRF, CLEC7A, TAC4
0.08
GOTERM_BP_FAT GO:0051606 ~ detection of stimulus 0.02 AIPL1, CASR, CLEC7A 13.23
INTERPRO IPR017452:GPCR, rhodopsin-like superfamily 0.009 OR4X1, OR5C1, GPR25, GALR2, OR7C2, MRGPRF 4.44
KEGG_PATHWAY hsa04740:Olfactory transduction 0.09 OR4X1, OR5C1, OR7C2 5.31
GOTERM_BP_FAT GO:0006954 ~ inflammatory response 0.02 C8B, CCL23, CLEC7A, CD163 6.40
GOTERM_BP_FAT GO:0006952 ~ defense response 0.02 C8B, CCL23, MPO, CLEC7A, CD163 4.23
GOTERM_BP_FAT GO:0006955 ~ immune response 0.03 C8B, CCL23, LST1, CLEC7A, TREM2 3.77
GOTERM_BP_FAT GO:0006874 ~ cellular calcium ion
homeostasis
0.04 CASR, CCL23, GALR2 8.53
GOTERM_BP_FAT GO:0030182 ~ neuron differentiation 0.04 LST1, NKX6-2, GALR2, EN2 4.75
GOTERM_CC_FAT GO:0005886 ~ plasma membrane 0.02 CASR, OR5C1, SLC7A9, MRGPRF, CDHR5, CD163, C8B,
OR4X1, ADAP2, GALR2, GPR25, OR7C2, CLEC7A, TREM2
1.65
GOTERM_CC_FAT GO:0005576 ~ extracellular region 0.071 KLKBL4, C8B, CCL23, MPO, TAC4, TREM2, CSN1S1, CD163 2.03
SP_PIR_ KEYW Disulfide bond 1.06E-12 KLKBL4, OR5C1, ALPK3, SLC7A9, GALNTL1, CSN1S1, CD163,
C8B, OR4X1, CCL23, GALR2, OR7C2, MPO, CLEC7A, TREM2
2.99
SP_PIR_ KEYW Glycoprotein 0.06 KLKBL4, CASR, OR5C1, MRGPRF, CDHR5, CD163, C8B,
OR4X1, GALR2, OR7C2, MPO, CLEC7A, TREM2
1.75
The analysis was performed by DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov). The genes associated with annotation terms with enrichment
p < 0.1 are reported here.
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have suffered from problems with replicability between
different laboratories. It is therefore important for any
results in this field to be confirmed and consolidated
through further investigations by independent laborator-
ies, using rigorous protocols and statistical evaluations.
The expression microarray analysis on whole genome, as
other high-throughput technologies assisted by bioinfor-
matics, could provide a strong clue as to the mechanism
of action and the biological relevance of ultra-low doses
and high dilutions interactions.
This is the first comparative transcriptomics approach
to investigate changes in the human neurocytes in-
duced by a natural plant remedy, traditionally used for
anxiolytic-like effects. The chief innovation of our ex-
perimental design is that it employs a wide range of
doses/dilutions. This enabled us to explore changes in
gene expression from low dilutions (2c or 3c), where
the active substances can still be expected to exert their
normal pharmaceutical action, to high dilutions (9c or 30c),
where the most controversial principles of high dilution
pharmacology come into play. Thus, both conventional
and ‘alternative’ pharmacological theories were evaluated
and compared in the same investigation. In previous
recent trials, Gelsemium s. showed anxiolytic-like effectsin mouse emotional response models and appeared to
work even at the high dilutions 9c and 30c [26,27]. Two
other studies have also found that high dilutions of
Gelsemium s. exert a preventive action against experimen-
tal stress (electric shock) in mice [29] and against convul-
sions provoked by lithium and pilocarpine in rats [5].
Other researchers have reported an anti-anxiety activity of
Gelsemium s. [12] and of the alkaloids gelsemine, koumine,
and gelsevirine [14,16], but have not explored the effect
of ultra-low doses and high dilutions/dynamizations.
To follow up on these in vivo studies, we decided to
investigate the action of Gelsemium s. at the cellular and
transcriptional level. We adopted a validated microarray
protocol and applied it to a series of replicate experi-
ments designed to test: a) the null hypothesis that the
effect of any Gelsemium s. dilutions is similar to that of
the control vehicle, b) whether any dose-dependence of
the putative effects can be demonstrated. As our model
system, we chose the SH-SY5Y and IMR-32 neurocyte
cell lines because these have been previously employed
for investigations of natural compounds [31], neuro-
trophic factors [32], mood stabilisers [59], and antipsy-
chotics [33]. In our conditions, this line proved to be
more responsive to Gelsemium s. than IMR-32 and was
used to compare the effects of high dilutions. The cells
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cium increase following treatment with the neurotrans-
mitter carbachol, and none of the Gelsemium s. dilutions
affected their growth rate or metabolic activity.
Low-dilution effects
The most evident and statistically significant modifica-
tion of cellular gene expression was induced by the low-
est dilution of the medicine that we tested, namely
Gelsemium s. 2c, as is to be expected with a dose-
dependent effect. Spectroscopic analysis of the tested
samples confirmed that the starting 1c solution supplied
by manufacturer contained a considerable amount of
original extract compounds, and proportionate quan-
tities were also detected in the 2c dilutions prepared
both by the manufacturer and in our laboratory. How-
ever, dilution equal or beyond 3c brought the concentra-
tion of detectable compounds below the minimum
sensitivity threshold of optical spectroscopy.
Although Gelsemium s. contains several different com-
pounds [2,3], the major active alkaloid of this plant is
gelsemine, which was present in a concentration of
6.5 × 10−9 M in the final incubation mixture of cells
treated with Gelsemium s. 2c. This nanomolar dosage is
much lower than the toxic doses that have been reported
in poisoning cases [60] and in experimental evaluations
of LD50 [14]. In fact, Gelsemium s. 2c at the lowest dilu-
tion (highest dose) tested in this model system did not
cause cell toxicity or viability impairment. This evidence
is in agreement with recent hypotheses explaining the
homeopathic effects (in the range of very low doses) in
the framework of hormesis, where substance which are
toxic at high doses turn into therapeutic when diluted to
low and ultra-low doses [61]. According to the hormetic
theory, ultra-diluted drugs and nanoparticles will act as
low-dose stress conditions that could possibly evoke an
adaptive response process producing effects that might
modulate gene expression [62-64].
The effects on gene expression observed here are spe-
cifically targeted to the regulation of certain functions,
possibly linked with the plant’s pharmacological activity.
Of a total of 45033 transcripts, 49 were down-regulated
and 7 up-regulated by the 2c dilution. This effect was
quantitatively small (absolute value of fold change be-
tween 0.5 and 1.0) but statistically significant (adjusted
p < 0.05). In general, the prevalence of down-regulation
seems to indicate a tendency to reduce cell excitability,
especially because several of the genes in question be-
long to surface receptors involved in GPCR signaling
and calcium homeostasis. Moreover, this first microarray
screening of the effects of Gelsemium s. on neurocytes
revealed a significant down-regulation of genes for inflam-
matory response, olfactory transduction and neuron dif-
ferentiation. Clearly, this plant species contains a varietyof active chemical principles which are presumably in-
volved in different pathways of cell regulation besides the
pure neural function, as suggested by reports of possible
anticancer and immunomodulating activities [17-19].
A hypothetical neurological target of Gelsemium s. has
been suggested by studies showing that gelsemine stimu-
lates the biosynthesis of allopregnanolone in the rat
brain [30,65], but the genes of neurosteroid enzymatic
pathways were not modulated in our cell system. This
apparent discrepancy may depend either on the fact that
we used a cell line, whereas Venard et. al. [30,65] used
slices of spinal cord and limbic system, or on the fact
that they studied a post-translational level of regulation,
linked to enzyme function and not to gene expression.
In any case, since in our model the effects of Gelsemium
s. were quantitatively small, as confirmed by RT-PCR re-
sults, no definite conclusions regarding the role of single
genes in the action mechanism of this plant can be
drawn at this stage.
These microarray findings can be regarded as a pre-
liminary screening of the sensitivity of SH-SY5Y cellular
system to Gelsemium s., while more robust conclusions
about the possible role of the implicated genes will
require to determine whether proteins encoded by the
affected genes are similarly changed, through proteomic
and phosphoproteomic approaches, and/or further stud-
ies using plant purified active compounds.
Ultra-low doses and high dilutions
The second major goal of this investigation was to study
the dose-effect relationship, which is of central import-
ance in any kind of pharmacological approach. As noted
above, the Gelsemium s. 2c dilution yielded statistically
significant results for 56 genes. This raised the question
of whether those same genes, which appeared to be most
sensitive to Gelsemium s., would also be modified by
higher dilutions. Since the quantitative changes for the
3c and higher dilutions were quite low (Table 3 and
Figure 7B), the 4 replicates were insufficient to yield stat-
istical confidence for analysis of single transcripts. We
therefore employed cluster analysis to separately de-
scribe the trends of 6 gene subsets with similar expres-
sion profiles. All 4 down-regulated clusters included
genes with negative mean fold changes, though of vary-
ing magnitude. Most notably, we found two clusters
(2 and 3 in Figure 7) that included a total of 24 genes
clearly responsive to Gelsemium s. 30c, and character-
ized by a bell-shaped dilution-effect curve. Exploring
results accurately (Table 3), some genes showed an inter-
esting pattern of expression in function of Gelsemium
dilution. For instance, the EN2 gene that was under-
expressed in treated cells exhibited a bell-shaped curve.
This tendency can be seen in other genes in the cluster
analysis. Moreover, it seems that after 9c, another wave
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future testing even higher dilutions, such as 100c or 200c,
the bell-shaped curve could be more evident and, thus,
the hypothesis of ultra-sensible genes could be checked.
For the high dilutions, due to the small changes of
gene expression, the only hypothesis statistically evalu-
able is the global effect of Gelsemium s. dilutions on the
49 down-regulated and 7 up-regulated genes, considered
as gene-sets. Using the Fisher exact test (Gelsemium s.
dilutions vs. their respective control solutions), the null
hypothesis was rejected for every dilution in the down-
regulated gene-set. This outcome of our microarray
analysis is astounding if we consider that the 9c and 30c
dilutions were obtained from MT extract by dilution
factors of 1018 and 1060 respectively. Starting from a
crude MT containing the active principle gelsemine at a
concentration of 6.5 × 10−4 M, the 9c dilution would the-
oretically contain 6.5 × 10−22 M gelsemine, correspond-
ing to less than 1 molecule per ml in the final working
solution; even in the case of the 5c dilution, where the
theoretical gelsemine concentration is 6.5 × 10−15 M, it
can be calculated that this would correspond to 3.9 × 107
molecules per culture plate, i.e. about 13 molecules per
seeded cell. These results suggest that neurocytes have a
number of genes with extreme sensitivity to Gelsemium
s. effects, even if those effects of high dilutions are quan-
titatively very small (decrease in expression by approxi-
mately 10% to 20% compared to the control). The
physiological or pharmacological implications of this
observation remain to be clarified, but the rejection of
the null hypothesis furnishes a new input for the open
debate on this kind of therapeutic approach.
Technical issues and confounding factors
The puzzling evidence of gene expression changes under
the influence of homeopathic dilutions prompt an
analysis of the possible confounding factors that might
explain the effects observed. We adopted different
measures to address the issue of possible experimental
artifacts. To avoid dye-bias artifacts a single-channel
microarray was employed. We adopted a microarray
design with probes of the same probe-set located in
not contiguous positions on the array, so that artifacts
due to uneven hybridization would only affect a subset
of probes for a probe-set. Anyhow, the absence of
spatial biases in fluorescence signal was assessed by
checking the coefficient of variation of the mean signal
intensities of different portions of each array. The experi-
mental set up could have introduced biases and “position
effects” if handling of control and Gelsemium s. matched
dilutions was not equivalent. Actually, we conducted four
independent experiments in which Gelsemium s. dilutions
and the corresponding vehicle controls were processed in
tandem (from drug addition to RNA extraction and cDNAsynthesis). In every subarray of the chip, each transcript
was targeted with three separate probes, merging the
fluorescence values and attributing a statistical score.
Regarding the statistical analysis, the large number of
genes of the complete set causes some problems con-
cerning the choice of “interesting” genes. The approach
followed here was quite stringent and limited the num-
ber of genes considered, reducing the probability of
“false positive” results, but forcing to discard some pos-
sibly interesting genes from the analysis. Moreover, the
small entity of the expression changes observed with
high dilutions unavoidably reduced statistical inference
in the single genes, especially since multiplicity correc-
tions were applied. The choice of analyzing the sign of
the fold changes in a pool of genes, rather than the vari-
ance of a single gene, may lead to a loss of statistical
information, to the advantage of greater precision in dis-
carding the null hypothesis. Further research specifically
oriented on the most responsive genes, with suitable
sample sizes, could possibly overcome this limitation of
the microarray approach.
Physico-chemical and biological hypotheses
Our results are in keeping with a number of experimen-
tal observations from a variety of research fields, con-
firming that highly diluted compounds exert statistically
significant effects on biological systems [66-69]. Thus far
there is no satisfactory or unifying theoretical explanation
for these claims, though some have hypothesized that the
dynamics of the solvent water (or water-ethanol) on a
mesoscopic scale may play a part [70]. Three major
models for how this happens are currently being inves-
tigated: the water clusters or clathrates, the coherent
domains postulated by quantum electrodynamics, and
the formation of nanoparticles from the original solute
plus solvent components. It has been suggested that a
major role in the formation of water clusters is played
by silica released from the glass containers which are
usually employed in the preparation of homeopathic
drugs [71]. Silica nanostructures formed during succus-
sion in glass and/or biosynthesized by specific plant ex-
tract tinctures may also acquire and convey epitaxial
information from the remedy source materials into the
higher potencies [21,72,73]. In our experimental model,
since the verum were succussed samples, we used the
succussed ethanol/water solutions as negative controls
and evaluated preliminarily the variability of the nega-
tive system before assessing the biological effect of the
succussed/diluted drug. Notably, in our experiments serial
dilutions/succussions were performed in glass bottles,
with the exception of the last step, which was developed
in polystyrene tubes. Thus the hypothetical role of silicates
in nanoparticle formation is pertinent, but also the contri-
bution of polystyrene should not be excluded [74].
Marzotto et al. BMC Complementary and Alternative Medicine 2014, 14:104 Page 18 of 20
http://www.biomedcentral.com/1472-6882/14/104Recent evidence supports the plausibility that homeo-
pathic Gelsemium s. in the potencies tested could con-
tain crudely formed nanoparticles. Bel-Haaj et al. [75]
demonstrated that just extended ultrasonication of plant
starch can create starch nanoparticles in water. Moreover,
electron microscopic evidence of nanoparticles has been
obtained in several different plants prepared homeopathic-
ally [76]. Gelsemium mother tincture itself, like many
other plant extracts, can biosynthesize nanoparticles of
silver metal from precursor substrate [77]. Nanoparticles
have unique biological and physicochemical properties,
including increased catalytic reactivity, protein and DNA
adsorption, bioavailability, dose-sparing, electromagnetic,
and quantum effects that are different from those of bulk-
form materials [23]. As an example, Prakash and col-
leagues [78] compared in model animals the anti-anxiety
effects of hypericum prepared as gold nanoparticles versus
a bulk form and observed more significant effects with the
nano-hypericum, even at a 10-fold lower dose. Higher
cellular uptake of nano-encapsulated (poly lactide-co-
glycolide) Gelsemium s. than of its bulk form has been
observed by Bhattacharyya et al. [79].
The hypotheses regarding the possible biological mecha-
nisms of highly diluted/dynamized solutions (beyond
Avogadro-Loschmidt limit) at the level of DNA expres-
sion variously invoke sensitivity to bioelectromagnetic
information, participation of water chains in signaling,
stochastic resonance, and regulation of bifurcation
points of nonlinear systemic networks [64,80-83]. Based
on microarray data, it has been suggested that gene
regulatory networks may be regarded as dynamically
‘critical’ systems poised near the phase transition be-
tween order and chaos [80,84,85], where extreme sensi-
tivity to initial conditions and small perturbations is
well known to occur. Chaotic regimes have been found
in a number of physiological systems, including neural
systems [86-88], and this would result in enhanced sus-
ceptibility to extremely low energy inputs and to small
changes of regulatory factors. According to this argument,
the highly diluted drug might be regarded as a solution
endowed with water clusters and/or nanoparticulate struc-
tures capable of communicating some pharmacological
information, through a resonance process, to biological
fluids and to cell critical systems such as macromolecules,
alpha-helixes, filamentous structures, receptors and DNA
networks. This effect could be mediated by the participa-
tion of a dynamic intracellular water network which may
be presumed to exist in living cells [89].
Conclusions
This study provides evidence that Gelsemium s. exerts a
prevalently inhibitory effect on a series of neurocyte
genes across a wide dose-range. The effect decreases
with increasing dilutions, but whole genome expressionanalysis allowed to detect statistically significant changes
even at the highest dilutions tested (9c and 30c). The
results suggest the extreme sensitivity of human gene
expression to regulation by ultra-low doses and high
dilutions/dynamizations of a plant remedy and encour-
age further efforts in research on this field. Studies using
“omic-based” approaches and systems biology should be
particularly worthy at generating new hypotheses on
mechanisms for the effects of highly diluted natural
compounds.
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